Thomas Charles Heineman Purchases 12,132 Shares of Oncolytics Biotech (NASDAQ:ONCY) Stock

February 14, 2026 by InsiderTrades.com

Key Points

Insider Thomas Charles Heineman purchased 12,132 shares of Oncolytics Biotech on Feb. 12 at $0.83 per share, raising his holdings to 282,818 shares (a 4.48% ownership increase) per an SEC filing.
Several other senior insiders — including the CEO, multiple directors, the VP and the CFO — also bought shares across Feb. 11–12, signaling a notable insider buying trend.
ONCY trades around $1.06 with a market cap of about $112.5M and a 52‑week range of $0.33–$1.51; analysts show mixed views but an average rating of "Moderate Buy" and an average price target of $6.25.

Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) insider Thomas Charles Heineman bought 12,132 shares of the stock in a transaction on Thursday, February 12th. The stock was purchased at an average price of $0.83 per share, for a total transaction of $10,069.56. Following the completion of the purchase, the insider owned 282,818 shares of the company's stock, valued at approximately $234,738.94. This trade represents a 4.48% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Oncolytics Biotech Price Performance

Shares of NASDAQ ONCY opened at $1.06 on Friday. The stock has a market capitalization of $112.52 million, a PE ratio of -3.79 and a beta of 0.99. Oncolytics Biotech Inc. has a one year low of $0.33 and a one year high of $1.51. The business's fifty day moving average price is $0.98 and its 200-day moving average price is $1.07.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.02. As a group, equities analysts expect that Oncolytics Biotech Inc. will post -0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ONCY. Seeds Investor LLC raised its position in shares of Oncolytics Biotech by 17.8% in the second quarter. Seeds Investor LLC now owns 223,767 shares of the company's stock worth $173,000 after buying an additional 33,826 shares in the last quarter. Citadel Advisors LLC purchased a new position in Oncolytics Biotech during the third quarter worth about $535,000. Scientech Research LLC bought a new position in Oncolytics Biotech in the 3rd quarter worth about $25,000. Ground Swell Capital LLC bought a new position in Oncolytics Biotech in the 4th quarter worth about $30,000. Finally, CIBC Private Wealth Group LLC purchased a new stake in shares of Oncolytics Biotech in the 4th quarter valued at about $44,000. 6.82% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Oncolytics Biotech

Here are the key news stories impacting Oncolytics Biotech this week:

Positive Sentiment: Director Patricia S. Andrews bought 35,400 shares at $0.86 (raising her stake 82.85% to 78,128 shares). SEC Filing
Positive Sentiment: Insider Andrew Aromando purchased 29,600 shares at $0.86 (increasing his position 116.08% to 55,100 shares). SEC Filing
Positive Sentiment: Director Bernd R. Seizinger acquired a total of 100,000 shares across Feb. 11–12 (60k at $0.83 and 40k at $0.85), boosting his holdings to ~566,991 shares. SEC Filing
Positive Sentiment: VP Allison Hagerman bought 10,000 shares at $0.83 (raising her stake ~9.5% to 115,059 shares). SEC Filing
Positive Sentiment: Director Deborah M. Brown purchased 25,000 shares at $0.85 (a ~29.5% increase; now ~109,851 shares). SEC Filing
Positive Sentiment: Insider Thomas C. Heineman bought 12,132 shares at $0.83 (increasing to ~282,818 shares). SEC Filing
Positive Sentiment: Director Wayne Pisano purchased 30,000 shares at $0.84 (raising his stake ~6.5% to ~492,414 shares). SEC Filing
Positive Sentiment: CFO Kirk Look bought 12,000 shares at $0.84 (increasing to ~287,515 shares). SEC Filing
Positive Sentiment: CEO Jared Kelly purchased a total of 35,100 shares across Feb. 11–12 at ~$0.84 (bringing his holdings to ~109,000 shares, a ~37% increase). SEC Filing

Analysts Set New Price Targets

ONCY has been the topic of a number of recent research reports. Zacks Research raised shares of Oncolytics Biotech from a "hold" rating to a "strong-buy" rating in a report on Friday, October 17th. HC Wainwright increased their target price on Oncolytics Biotech from $5.00 to $10.00 and gave the stock a "buy" rating in a research report on Monday, November 17th. Wall Street Zen cut Oncolytics Biotech from a "hold" rating to a "sell" rating in a research report on Saturday, November 15th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Oncolytics Biotech in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $6.25.

Get Our Latest Analysis on Oncolytics Biotech

Oncolytics Biotech Company Profile

(Get Free Report)

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company's lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.